Progyny, Inc. (NASDAQ:PGNY – Get Rating) Director Norman Payson sold 6,618 shares of the firm's stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $32.27, for a total value of $213,562.86. Following the transaction, the director now directly owns 411,412 shares of the company's stock, valued at approximately $13,276,265.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Norman Payson also recently made the following trade(s):
Get Progyny alerts:- On Wednesday, July 20th, Norman Payson sold 6,618 shares of Progyny stock. The stock was sold at an average price of $33.40, for a total value of $221,041.20.
- On Wednesday, July 6th, Norman Payson sold 6,618 shares of Progyny stock. The stock was sold at an average price of $29.38, for a total value of $194,436.84.
- On Wednesday, June 22nd, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $27.35, for a total value of $181,002.30.
- On Wednesday, May 25th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $32.09, for a total value of $212,371.62.
- On Wednesday, May 11th, Norman Payson sold 6,618 shares of Progyny stock. The shares were sold at an average price of $33.45, for a total value of $221,372.10.
Progyny Stock Up 38.2 %
Shares of NASDAQ:PGNY opened at $41.15 on Friday. The company has a market cap of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 15.71 and a beta of 1.85. Progyny, Inc. has a 52 week low of $25.67 and a 52 week high of $68.32. The business has a fifty day simple moving average of $30.23 and a 200-day simple moving average of $37.34.
Progyny (NASDAQ:PGNY – Get Rating) last issued its earnings results on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.04. Progyny had a return on equity of 18.11% and a net margin of 7.39%. The firm had revenue of $195.00 million for the quarter, compared to analysts' expectations of $190.51 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm's revenue for the quarter was up 51.5% compared to the same quarter last year. Sell-side analysts expect that Progyny, Inc. will post 0.09 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its holdings in Progyny by 39.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 14,408 shares of the company's stock valued at $419,000 after acquiring an additional 4,040 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in Progyny in the second quarter valued at $442,000. Los Angeles Capital Management LLC boosted its holdings in Progyny by 25.0% in the second quarter. Los Angeles Capital Management LLC now owns 12,536 shares of the company's stock valued at $364,000 after acquiring an additional 2,511 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in Progyny by 69.2% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 441,903 shares of the company's stock valued at $12,837,000 after acquiring an additional 180,800 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS acquired a new position in shares of Progyny during the second quarter worth about $3,167,000. Institutional investors and hedge funds own 82.51% of the company's stock.
Progyny Company Profile
(Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Stories
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.